全文获取类型
收费全文 | 19834篇 |
免费 | 2554篇 |
国内免费 | 450篇 |
专业分类
耳鼻咽喉 | 72篇 |
儿科学 | 981篇 |
妇产科学 | 130篇 |
基础医学 | 2008篇 |
口腔科学 | 155篇 |
临床医学 | 3057篇 |
内科学 | 3990篇 |
皮肤病学 | 188篇 |
神经病学 | 623篇 |
特种医学 | 395篇 |
外科学 | 844篇 |
综合类 | 3607篇 |
现状与发展 | 2篇 |
一般理论 | 1篇 |
预防医学 | 2435篇 |
眼科学 | 248篇 |
药学 | 2284篇 |
38篇 | |
中国医学 | 954篇 |
肿瘤学 | 826篇 |
出版年
2024年 | 91篇 |
2023年 | 380篇 |
2022年 | 898篇 |
2021年 | 1236篇 |
2020年 | 1449篇 |
2019年 | 833篇 |
2018年 | 878篇 |
2017年 | 1017篇 |
2016年 | 1105篇 |
2015年 | 1031篇 |
2014年 | 1710篇 |
2013年 | 1654篇 |
2012年 | 1424篇 |
2011年 | 1455篇 |
2010年 | 1012篇 |
2009年 | 842篇 |
2008年 | 776篇 |
2007年 | 804篇 |
2006年 | 685篇 |
2005年 | 540篇 |
2004年 | 531篇 |
2003年 | 505篇 |
2002年 | 326篇 |
2001年 | 232篇 |
2000年 | 205篇 |
1999年 | 175篇 |
1998年 | 152篇 |
1997年 | 132篇 |
1996年 | 98篇 |
1995年 | 90篇 |
1994年 | 76篇 |
1993年 | 55篇 |
1992年 | 65篇 |
1991年 | 54篇 |
1990年 | 40篇 |
1989年 | 40篇 |
1988年 | 42篇 |
1987年 | 26篇 |
1986年 | 20篇 |
1985年 | 27篇 |
1984年 | 21篇 |
1983年 | 19篇 |
1982年 | 13篇 |
1981年 | 15篇 |
1980年 | 12篇 |
1979年 | 13篇 |
1978年 | 8篇 |
1977年 | 10篇 |
1976年 | 6篇 |
1975年 | 3篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
71.
Children with recurrent lower respiratory tract infection (RLRI) may respond poorly to polysaccharide antigens. To examine how such children respond to a polysaccharide coupled to a protein carrier, we immunized 15 children with RLRI aged 8–69 months and 15 carefully age-matched healthy controls once with a Haemophilus influenzae type b (Hib) conjugate vaccine. Total IgG subclasses, total antipolysaccharide Hib antibodies, and antipolysaccharide Hib antibodies of IgM, IgG, IgA, and IgG 1–4 specificity were determined by ELISA. There were no significant differences between the two groups in any single total IgG subclass, but total IgG measured as the sum of all four subclasses was significantly lower in the children with RLRI than in the controls ( P = 0.036). Before vaccination, the children with RLRI had significantly less IgG antipolysaccharide Hib antibody than the controls ( P = 0.005), whereas 1 month later they had significantly more IgM antibody (P = 0.038). No other significant differences were found between the groups before or after immunization with respect to antipolysaccharide Hib antibodies. Since naturally occurring IgG antibodies are thought to be aquired partly as a consequence of antigenic stimulation on mucosal surfaces, we hypothesize that the low level of specific IgG found before immunization, as well as the low total IgG in the children with RLRI, may reflect an impaired ability to prime through mucosal surfaces. This is supported by our finding of an increased IgM response to Hib conjugate vaccine in these children, since this isotype predominates in the primary immune response, i.e., in the absence of immunologic memory. In conclusion, children with RLRI can be protected against invasive Hib infection as well as healthy children, but may have an immunodeficiency characterized by defective ability to respond to antigenic stimulation on mucosal surfaces. 相似文献
72.
目的探讨环氧化物酶-2(cyclooxygenase type 2,COX-2)及Ⅰ型前列腺素合成酶(membrane associated prostaglandin E-1,mPGES-1)在人颈动脉粥样硬化斑块中的表达变化及作用机制。方法收集24例人颈动脉粥样硬化斑块标本和10例肠系膜动脉标本做对照组,应用免疫组织化学及逆转录PCR方法测定COX-2及mPGES-1mRNA表达水平,Western印记方法检测COX-2及mPGES-1的蛋白表达水平。比较不同程度动脉粥样硬化组织间COX-2、mPGES-1 mRNA表达水平及蛋白表达水平。结果颈动脉粥样硬化斑块组的免疫组织化学染色检测COX-2和mPGES-1呈阳性表达,斑块组COX-2 mRNA和mPGES-1 mRNA表达与对照组相比上调,差异有统计学意义(P<0.05);COX-2及mPGES-1 mRNA上调水平相关(P<0.05);颈动脉粥样硬化斑块的COX-2蛋白表达上调水平与对照组相比差异有统计学意义(P<0.05);颈动脉粥样硬化斑块COX-2、mPGES-1 mRNA及蛋白表达水平与病理损害程度有关,差异有统计学意义(P<0.05)。结论COX-2及mPGES-1基因表达水平上调可能是进展性动脉粥样硬化损害的关键因素。 相似文献
73.
目的 检测肺鳞状细胞癌中死亡相关蛋白激酶 (DAP K)mRNA表达及细胞凋亡 ,探讨DAP K与细胞凋亡的关系及其在肺鳞状细胞癌发生、发展中的作用。方法 用原位分子杂交法检测 6 0例肺鳞状细胞癌、9例癌旁肺组织DAP KmRNA表达 ;用原位末端标记TUNEL法检测相应组织中细胞凋亡 ,计算凋亡指数 (AI)。结果 肺鳞状细胞癌的DAP KmRNA阳性表达率为 4 6 7% ,癌旁肺组织为 6 7 7% ,其阳性率高于肿瘤组织 (P <0 0 1 )。在肺鳞状细胞癌中 ,高分化癌DAP KmRNA阳性率为 70 % ,低分化癌为 2 3 3% ,高分化癌的DAP KmRNA阳性率高于低分化癌 (P <0 0 1 )。肺鳞状细胞癌的细胞AI为(0 6 72 8± 0 4 2 6 1 ) % ,癌旁肺组织中支气管肺泡上皮细胞AI为 (1 0 2 89± 0 2 4 33) % ,癌旁肺组织的AI高于肿瘤组织 (P<0 0 1 )。在肺鳞状细胞癌中 ,高分化癌的AI为 (0 5 82 3± 0 1 92 2 ) % ,低分化癌为 (0 4 4 6 0± 0 1 92 5 ) % ,高分化癌的AI高于低分化癌 (P <0 0 1 )。DAP KmRNA呈阳性表达的肺癌 ,其AI为 (0 5 31 7± 0 2 0 97) % ;DAP KmRNA呈阴性者 ,其AI为 (0 4 872± 0 1 91 8) % ,两组间差异有显著性 (P <0 0 5 )。在连续切片上 ,DAP KmRNA阳性细胞的分布区域与凋亡阳性细胞的分布相似。DAP KmRNA呈阳性表达 相似文献
74.
重症监护病房中呼吸机相关肺炎的病原学和耐药性特征 总被引:2,自引:0,他引:2
目的探讨重症监护病房(ICU)中呼吸机相关肺炎(VAP)的流行病学、病原菌分布、耐药性特征。方法对广州市3所三级甲等医院ICU发生VAP的53例患者进行前瞻性研究,对病原菌进行细菌鉴定和耐药性分析。结果VAP平均发病时间为机械通气后7.8d。97株病原菌中革兰阴性细菌58株(59.8%),革兰阳性细菌23株(23.7%),真菌16株(16.5%)。最常见病原菌分别为铜绿假单胞菌16株(16.5%),金黄色葡萄球菌13株(13.4%),嗜麦芽窄食单胞菌8株(8.2%),肺炎克雷伯菌8株(8.2%),白色念珠菌8株(8.2%)。耐甲氧西林金黄色葡萄球菌(MRSA)检出率为100.0%;未发现耐万古霉素金黄色葡萄球菌;VAP病原菌存在严重的多重耐药性。结论ICU中VAP的病原菌构成以革兰氏阴性杆菌为主且呈现多重耐药现象,适当的经验性抗菌治疗应以病原学和耐药性的监测结果为依据。 相似文献
75.
胃粘膜相关淋巴组织型淋巴瘤形态学研究 总被引:12,自引:5,他引:12
目的:研究胃粘膜相关淋巴细胞(MALT)型淋巴瘤及共与胃粘膜套细胞淋巴瘤和滤泡性淋巴瘤的鉴别诊断。方法:应用HE染色和免疫组化ABC法检测胃MALT型淋巴瘤,内镜作幽门螺杆菌培养基尿素试验检测HP感染。结果:31例胃MALT型淋巴瘤中低度恶性27例,高度恶性4例。细胞类型以CCL型最常见。免疫表型以IgM为主,缺乏IgD,31例中28例有HP感染(占90.52%),结论:(1)低恶MALT型淋巴瘤 相似文献
76.
Forty-three bronchoalveolar lavage (BAL) specimens from 40 immunocompromised patients were studied for the presence of cytomegalovirus (CMV) by rapid diagnostic methods. DNA in situ hybridization, cytology, and immunofluorescence were compared to conventional cell culture. Eleven (25%) of the 43 BAL samples grew CMV in culture. In situ hybridization detected 6 of these 11 for sensitivity, specificity, and predictive values of positive and negative of 55%, 94%, 75%, and 86%, respectively. Cytology had a sensitivity of 73% and specificity of 100%. Six Papanicolaou-stained cytospins were screened cytologically versus one hybridization cytospin, and the higher sensitivity of cytology may reflect this extensive sampling. The immunofluorescent method had a sensitivity equal to that of cytology (73%): however, the specificity (72%) was significantly less than that of either the probe or cytology. These data suggest that although in situ hybridization can be a rapid, useful method for detecting CMV in BAL specimens, cytology appears to be a more sensitive method. 相似文献
77.
Payeras A Martinez P Milà J Riera M Pareja A Casal J Matamoros N 《Clinical and experimental immunology》2002,130(2):271-278
The aim of the study was to determine possible factors related to the risk of developing recurrent bacterial respiratory tract infections in HIV-1-infected patients, regardless of the degree of immune cellular impairment. Thirty-three HIV-1 seropositive patients with previous repetitive bacterial respiratory tract infections (case group), 33 HIV-1 seropositive controls (matched by CD4-cell counts) without these antecedents and 27 healthy controls were studied before and after administration of pneumococcal and Haemophilus influenzae type b vaccines. Clinical or toxicological variables, cutaneous tests, complement factors, beta2-microglobulin, serum IgM, IgA, IgG and subclasses, specific antibodies (IgG, IgG2, IgA) against pneumococcal vaccine and polyribosylribitol phosphate (PRP), their avidity, opsonophagocytosis and IgG(2)m and Fc(gamma)RIIa allotypes were determined. A history of drug abuse (P = 0.001), less likelihood of receiving high activity antiretroviral treatment high activity antiretroviral treatment (HAART) (P = 0.01), higher levels of HIV-1 viral load (P < 0.05), serum IgG (P < 0.01) and beta2-microglobulin (P < 0.01) were observed in the case group. Also, a lower increase in specific antibodies to pneumococcal vaccine and PRP was demonstrated in the cases in comparison with the two control groups. No differences were observed in the avidity of antibodies, opsonophagocytic capacity or IgG(2)m and Fc(gamma)RIIa allotypes between the three groups. These data indicate that vaccination strategies against encapsulated bacteria can be unsuccessful in the HIV-1-infected patients presenting repetitive bacterial respiratory tract infections if behavioural aspects or measures to improve adherence to HAART therapies are not considered. 相似文献
78.
H. Lode P. Magyar J. F. Muir U. Loos K. Kleutgens 《Clinical microbiology and infection》2004,10(6):512-520
A double-blind, double-dummy, multicentre, multinational, parallel-group study was designed to establish proof of equivalence between oral gatifloxacin and oral co-amoxiclav in the treatment of 462 patients with mild-to-moderate community-acquired pneumonia. Eligible patients were randomised equally to either gatifloxacin 400 mg once-daily plus matching placebo for 5-10 days, or amoxycillin 500 mg + clavulanic acid 125 mg three-times-daily for 5-10 days. The primary efficacy endpoint was clinical response (clinical cure plus improvement) at the end of treatment. Overall, a successful clinical response was achieved in 86.8% of gatifloxacin-treated patients, compared with 81.6% of those receiving co-amoxiclav, while corresponding rates of bacteriological efficacy (eradication plus presumed eradication) were 83.1% and 78.7%, respectively. The safety and tolerability profile of gatifloxacin was comparable to that of co-amoxiclav, with adverse gastrointestinal events, e.g., diarrhoea and nausea, being the most common treatment-related adverse events in both groups. The study showed no evidence of gatifloxacin-induced phototoxicity, musculoskeletal disorders, or hepatic and renal problems. Overall, this study showed that gatifloxacin was equivalent clinically to a standard course of co-amoxiclav in patients with community-acquired pneumonia, and that gatifloxacin was safe and well-tolerated. 相似文献
79.
M. Tamm T. Todisco C. Feldman J. Garbino F. Blasi P. Hogan P. J. de Caprariis I. M. Hoepelman 《Clinical microbiology and infection》2007,13(2):162-171
This study compared patients with moderate-to-severe community-acquired pneumonia (CAP) requiring hospitalisation, who received initial therapy with either intravenous ceftriaxone plus intravenous azithromycin, followed by step-down to oral azithromycin (n = 135), with patients who received intravenous ceftriaxone combined with either intravenous clarithromycin or erythromycin, followed by step-down to either oral clarithromycin or erythromycin (n = 143). Clinical and bacteriological outcomes were evaluated at the end of therapy (EOT; day 12-16) or at the end of study (EOS; day 28-35). At baseline, mean APACHE II scores were 13.3 and 12.6, respectively, with >50% of patients classified as Fine Pneumonia Severity Index (PSI) category IV or V. Clinical success rates (cure or improvement) in the modified intent-to-treat (MITT) population at EOT were 84.3% in the ceftriaxone/azithromycin group and 82.7% in the ceftriaxone/clarithromycin or erythromycin group. At EOS, MITT success rates (cure only) were 81.7% and 75.0%, respectively. Equivalent success rates in the clinically evaluable population were 83% and 87%, respectively, at EOT, and 79% and 78%, respectively, at EOS. MITT bacteriological eradication rates were 73.2% and 67.4%, respectively, at EOT, and 68.3% vs. 60.9%, respectively, at EOS. Mean length of hospital stay (LOS) was 10.7 and 12.6 days, and the mean duration of therapy was 9.5 and 10.5 days, respectively. The incidence of infusion-related adverse events was 16.3% and 25.2% (p 0.04), respectively. An intravenous-to-oral regimen of ceftriaxone/azithromycin was at least equivalent in efficacy and safety to the comparator regimen and appeared to be a suitable treatment option for hospitalised patients with CAP. 相似文献
80.
Krämer J Aguirre-Arteta AM Thiel C Gross CM Dietz R Cardoso MC Leonhardt H 《Journal of molecular medicine (Berlin, Germany)》1999,77(2):294-298
Studies on smooth muscle cell differentiation and those on vascular development in mouse and humans have long been hampered
by the lack of suitable markers. Here we describe a novel, large isoform of smoothelin, a structural protein of differentiated,
contractile smooth muscle cells. The protein, which is highly conserved in mouse and humans, shows homology with other cytoskeleton-associated
smooth muscle cell proteins and contains an actinin-type actin-binding domain. Northern blot analysis from various mouse organs
identified short and long smoothelin mRNA forms, which exhibit distinct tissue expression patterns. The short form is highly
expressed in visceral muscle tissues such as intestine and stomach and is not detectable in brain, while the long mRNA form
is expressed in all vascularized organs. These results may provide new tools and approaches to study both smooth muscle cell
differentiation and proliferative vascular disease.
Received: 25 August 1998 / Accepted: 19 October 1998 相似文献